ISSN 2149-2263 | E-ISSN 2149-2271
Natriuretic Peptides in Clinical Practice [Anatol J Cardiol]
Anatol J Cardiol. 2019; 21(Suppl 1): 1-40 | DOI: 10.14744/AnatolJCardiol.2019.55623

Natriuretic Peptides in Clinical Practice

Yüksel Çavuşoğlu1, Ahmet Taha Alper2, Hakan Altay3, Ahmet Çelik4, Burcu Demirkan5, Tolga Sinan Güvenç6, Mehmet Serdar Küçükoğlu7, Sanem Nalbantgil8, Murat Özdemir9, Bülent Özin10, Tamer Sayın11, Özlem Yıldırımtürk2, Mehmet Birhan Yılmaz12, Cafer Zorkun13
1Department of Cardiology, Faculty of Medicine, Eskişehir Osmangazi University, Eskişehir-Turkey
2Department of Cardiology, University of Health Sciences, Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, İstanbul-Turkey
3Department of Cardiology, Faculty of Medicine, Baskent University, İstanbul-Turkey
4Department of Cardiology, Faculty of Medicine, Mersin University, Mersin-Turkey
5Turkey Training and Research Hospital, Cardiology Clinic, Ankara-Turkey
6University of Alberta, Department of Medicine and Dentistry, Division of Cardiology, Alberta-Canada
7Department of Cardiology, Istanbul University, Cardiology Institute, İstanbul-Turkey
8Department of Cardiology, Faculty of Medicine, Ege University, İzmir-Turkey
9Department of Cardiology, Faculty of Medicine, Gazi University, Ankara-Turkey
10Department of Cardiology, Faculty of Medicine, Başkent University, Ankara-Turkey
11Department of Cardiology, Faculty of Medicine, Ankara University, Ankara-Turkey
12Department of Cardiology, Faculty of Medicine, Cumhuriyet University, Sivas-Turkey
13Department of Cardiology, Faculty of Medicine, Trakya University, Edirne-Turkey

Natriuretic peptides have long been introduced into clinical practice. These biomarkers have certainly been shown to provide useful information in the diagnosis, prognosis and risk stratification in heart failure and also may have a role in the guidance of heart failure therapy. Although, there are some limitations in using of these markers such as lack of specificity, aging, renal dysfunction or obesity, among the huge number of candidates for heart failure biomarkers, only natriuretic peptides are currently widely used in daily clinical practice in heart failure. Recent heart failure guidelines recognize natriuretic peptides as an essential tool in the new diagnostic and therapeutic algorithms. Furthermore, natriuretic peptides are not only used in the diagnosis or prognosis of heart failure, but also these biomarkers are referred to have some potential role in primary prevention, cardio-oncology, advanced heart failure, assessment of response to cardiac resynchronization therapy, pulmonary arterial hypertension, acute coronary syndromes, atrial fibrillation and valvular heart disease. In this article, natriuretic peptides have been reviewed for their updated information and new recommendations in heart failure and also potential role of these biomarkers in the management of various clinical conditions have been addressed in the form of expert opinion based on the available data in the literature.

Keywords: natriuretic peptides, heart failure

Yüksel Çavuşoğlu, Ahmet Taha Alper, Hakan Altay, Ahmet Çelik, Burcu Demirkan, Tolga Sinan Güvenç, Mehmet Serdar Küçükoğlu, Sanem Nalbantgil, Murat Özdemir, Bülent Özin, Tamer Sayın, Özlem Yıldırımtürk, Mehmet Birhan Yılmaz, Cafer Zorkun. Natriuretic Peptides in Clinical Practice. Anatol J Cardiol. 2019; 21(Suppl 1): 1-40

Corresponding Author: Yüksel Çavuşoğlu
Manuscript Language: English

Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
SCImago Journal Rank: 0.348

Quick Search

Copyright © 2024 The Anatolian Journal of Cardiology

Kare Publishing is a subsidiary of Kare Media.